TY - JOUR
T1 - Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis
AU - Hirano, Ikuo
AU - Rothenberg, Marc E.
AU - Zhang, Sandra
AU - De Oliveira, Claudia
AU - Charriez, Christina M.
AU - Coyne, Karin S.
AU - Bacci, Elizabeth Dansie
AU - Dellon, Evan S.
N1 - Funding Information:
Financial support: This study was supported by Bristol Myers Squibb. Writing and editorial assistance were provided by Claire Jarvis, PhD, and John Simmons, MD, of Peloton Advantage, an OPEN Health company, funded by Bristol Myers Squibb.
Publisher Copyright:
© 2023 Wolters Kluwer Health. All rights reserved.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.
AB - INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85151312438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151312438&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000002094
DO - 10.14309/ajg.0000000000002094
M3 - Article
C2 - 36647838
AN - SCOPUS:85151312438
SN - 0002-9270
VL - 118
SP - 744
EP - 747
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 4
ER -